EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Infliximab (Primary) ; Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms EFFICACI
- 05 Nov 2019 Planned End Date changed from 1 Jun 2022 to 4 Jan 2022.
- 05 Nov 2019 Planned primary completion date changed from 1 Dec 2020 to 4 Jan 2021.
- 05 Nov 2019 Status changed from not yet recruiting to recruiting.